Skip to main content

Viewpoint: Congress has put a bull's-eye on life sciences economy

Pioneer Institute fellow writes that Schumer-Manchin bill is bad for patients, a travesty for the New England life sciences economy, and hurts long-term drug affordability.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.